Neural stem cells and neural progenitor cells (NPCs) exist throughout life and are mobilized to replace neurons, astrocytes and oligodendrocytes after injury. Stromal cell-derived factor 1 (SDF-1, now named CXCL12) and its receptor CXCR4, an α-chemokine receptor, are critical for NPC migration into damaged areas of the brain. Our previous studies demonstrated that immune activated and/or HIV-1-infected human monocyte-derived-macrophages (MDMs) induced a substantial increase of SDF-1 production by human astrocytes. However, matrix metalloproteinase (MMP)-2, a protein up-regulated in HIV-1-infected macrophages, is able to cleave four amino acids from the N-terminus of SDF-1, resulting in a truncated SDF-1(5-67). In this study, we investigate the diverse signaling and function induced by SDF-1α and SDF-1(5-67) in human cortical NPCs. SDF-1(5-67) was generated by incubating human recombinant SDF-1α with MMP-2 followed by protein determination via mass spectrometry, Western blotting and ELISA. SDF-1α induced time-dependent phosphorylation of extracellular signal-regulated kinases (ERK) 1/2, Akt-1, and diminished cyclic adenosine monophosphate (cAMP). In contrast, SDF-1(5-67) failed to induce these signaling. SDF-1α activation of CXCR4 induced migration of NPCs, an effect that is dependent on ERK1/2 and Akt-1 pathways; whereas SDF-1(5-67) failed to induce NPC migration. This observation provides evidence that MMP-2 may affect NPC migration through post-translational processing of SDF-1α.
INTRODUCTION
Neural stem cells and neural progenitor cells (NPCs) exist in the adult mammalian central nervous system (CNS). Two important features of NPCs are self-renewal and multipotency, meaning NPCs can give rise to neurons, astrocytes, and oligodendrocytes and therefore replace lost cells in the CNS (Weiss et al., 1996; Alvarez-Buylla et al., 2000; Gage, 2000) . NPC migration is an essential process for neurogenesis that occurs in the adult CNS (Hatten, 1999; Gage, 2002) . Following injury to the CNS, NPCs preferentially migrate to damaged areas of the brain to facilitate repair, indicating that agents present in the damaged tissue guide the migration of precursor cells (Sun et al., 2004; Belmadani et al., 2006; Chi et al., 2006; Ke et al., 2006; Takeuchi et al., 2007; Wu, 2012) . Chemokines, such as stromal cell-derived factor (SDF)-1α, are important mediators of this process (Ceradini et al., 2004; Imitola et al., 2004) .
The CXC chemokine SDF-1, known as CXCL12, is a key regulator of B cell lymphopoiesis (Nagasawa et al., 1996; Ma et al., 1998) , hematopoietic stem cell mobilization (Aiuti et al., 1997) , and leukocyte migration. In addition to the immune system, SDF-1 and its receptor CXCR4 also have important functions in the nervous system. Both SDF-1 and CXCR4 are constitutively expressed at high levels in the developing and © Higher Education Press and Springer-Verlag Berlin Heidelberg 2012 adult nervous system (Bajetto et al., 1999; Peng et al., 2004; Tran et al., 2004; Peng et al., 2007) . SDF-1/CXCR4 signaling regulates the migration and development of neural stem cells that form numerous structures in the brain and peripheral nervous systems (Zou et al., 1998; Bagri et al., 2002; Lu et al., 2002; Reiss et al., 2002; Lazarini et al., 2003; Zhu et al., 2012) . Recent data have demonstrated that SDF-1/CXCR4 signaling continues to play a role in the regulation of adult neurogenesis in response to brain injury, and that cells proximal to areas of brain injury upregulate the expression of SDF-1 to attract progenitor cells for repair purposes (Ceradini et al., 2004; Imitola et al., 2004) . Previous studies in our lab demonstrated that HIV-1 infected and immunecompetent macrophages, which are the principal target cells and mediators of neuronal injury and death in HIV-1-associated dementia (HAD), induced a substantial increase in SDF-1 production by human astrocytes (Peng et al., 2006) . However, matrix metalloproteinase (MMP)-2, which is markedly upregulated in the brain and cerebrospinal fluid of patients with AIDS, could cleave the first four amino acids from the N-terminus of SDF-1, yielding a truncated SDF-1(5-67) (Conant et al., 1999; Johnston et al., 2000; Zhang et al., 2003) . Unlike SDF-1α, SDF-1(5-67) failed to bind to its cognate receptor, CXCR4, and caused neurotoxicity and apoptosis. However, whether SDF-1(5-67) affects NPC function, neurogenesis and potential repair processes remains unclear.
In this study, we investigate the diverse signaling and function induced by SDF-1α and SDF-1(5-67) in human cortical NPCs. We found that MMP-2 cleaves SDF-1α, yielding an N-terminally truncated SDF-1(5-67) that losses its ability to induce CXCR4 signaling and chemotactic function in human NPCs.
RESULTS

Proteolysis of SDF-1α by MMP-2
Modification of SDF-1α structure and function was investigated following in vitro exposure of the chemokine to active MMP-2. Human recombinant SDF-1α was incubated with active MMP-2 at different enzyme/substrate ratios. SDF-1α and reaction products was detected by Western blot analysis using either a monoclonal antibody (mAb), recognizing an epitope encoded in the amino-terminal part of the chemokine, or a polyclonal antibody (pAb), recognizing multiple epitopes of SDF-1α. We observed that incubation of SDF-1α with active MMP-2 (1:10 and 1:1, ratio of MMP-2 and SDF-1) led to the loss of the amino-terminal epitope recognized by the mAb (Fig. 1A) . The slight change on the electrophoretic mobility which revealed by pAb blot, proved the discrete modification undergone by the chemokine (Fig. 1B) .
Generation of cleavage product over time was measured using Western blot analysis with polyclonal antibody; which detects both cleaved and intact SDF-1α forms (Fig. 1C) . MMP-2-mediated cleavage of SDF-1α occurred with very similar kinetics, as previously described, with half of product being cleaved in 30-60 min (McQuibban et al., 2001) .
The amino-terminal cleavage of SDF-1α was also detected by RP-HPLC combined with ELISA. MMP-2 treated SDF-1α (1:10 ratio for MMP-2/SDF-1, w/w) and an untreated (1 μg) was incubated with MMP-2 (10 ng) at 37°C, and reaction products were taken at the following time points: 0, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h and 24 h. Reaction products were electrophoresed in 15% Tris-HCl SDS-PAGE and blotted with antibody for SDF-1 (polyclonal). Results are representative of three independent experiments. (D) SDF-1 (100 ng) and MMP-2-treated SDF-1 (with MMP-2/SDF-1α of 1:10 and incubated for 4 h) samples were passed through a RP-HPLC column, followed by subsequent detection of SDF-1 by ELISA. SDF-1α was present in fractions 42-46 min. SDF-1α control were separated by RP-HPLC and collected as fractions. The level of SDF-1 in each collected fraction was determined using a monoclonal SDF-1 antibody-based ELI-SA. The amino-terminal cleavage of SDF-1α was evident based on a significantly decreased peak of SDF-1 at 43 min (retention time) after the MMP-2 treatment (Fig. 1D) .
To identify SDF-1α residues cleaved by MMP-2, we analyzed SDF-1α degradation products by electrospray mass spectrometry. For this purpose, SDF-1α was incubated with MMP-2 for 4 h at 37°C and loaded to the chip pre-treated with anti-SDF-1 polyclonal antibody. A polypeptide of molecular mass 7538 Da was detected as the major molecular species generated upon cleavage and corresponded to an SDF-1α fragment lacking the amino-terminal Lys Fig. 2 ). This finding confirms that the amino terminus of SDF-1α is the proteolytic target by MMP-2.
SDF-1(5-67) failed to induce NPC signaling in human cortical NPCs
SDF-1 binds to the chemokine receptor CXCR4 and triggers signaling through a pertussis toxin-sensitive, G-protein-dependent, intracellular signaling pathway. We previously reported that SDF-1α binding to CXCR4 mediates trimeric GTP-binding G-inhibitory protein activation and induces inhibition of adenylate cyclase, activates MAP kinase and increases intracellular calcium in human and rat NPCs (Peng et al., 2004) . In this study, we examined if MMP-2 cleavage of four amino acids from N-terminus of SDF-1α will affect SDF-1α mediated NPC signaling. To generate SDF-1(5-67), we incubated recombinant SDF-1α with active MMP-2 (1:10 ratio of MMP-2 and SDF-1) for 4 h as described. As shown in Fig. 3 , SDF-1α inhibited FSK-stimulated cAMP production in a dose-dependent manner. SDF-1(5-67) showed a decreased effect compared to intact SDF-1α. Next, we examined the effects of SDF-1α on mitogen-activated protein (MAP) kinase extracellular signal-regulated kinases1/2 (ERK1/2), and Akt activation. Notably, after cleavage with MMP-2, the fragmented SDF-1α [SDF-1(5-67)] lost its ability to activate ERK1/2 and Akt (Fig. 4) .
Impaired chemotactic activity by SDF-1(5-67)
SDF-1 binds to its specific cell surface receptor, CXCR4, and is a potent chemoattractant for NPCs. We next examined if MMP-2 cleavage of SDF-1α will affect the ability of this chemokine to mediate NPC migration. The effect of SDF-1α and SDF-1(5-67) on NPC migration was tested by their abilities to direct chemotaxis across membranes in NeuroProbe chemotaxis chambers. SDF-1α induced concentration-dependent migration of NPCs. At the concentration that SDF-1α induced a significant NPC migration, its MMP-2 derived fragment, SDF-1(5-67), was unable to stimulate migration of NPCs (Fig. 5A ). SDF-1 binds and activates the chemokine receptor CXCR4 as well as the more recently identified CXCR7 receptor. However, SDF-1α-induced NPC migration was CXCR4 dependent as confirmed by the total inhibition by T140, a CXCR4 specific antagonist (Fig. 5B) . The migration can also be completely blocked by phosphoinositide 3-kinase inhibitors LY294002 and MAP kinase/ERK inhibitor (PD98059), whereas P38 inhibitor (SB203580) had no significant effect on SDF-1α-induced migration (data not shown). This result suggests the demissal of SDF-1(5-67) in NPC signaling may result in impaired chemotactic activity by SDF-1(5-67).
DISCUSSION
SDF-1, a constitutively expressed chemokine in the brain, is vital for normal brain development and tissue homeostasis. In addition to transcriptional regulation of expression following cytokine exposure (Peng et al., 2006) , SDF-1 expression is also regulated at post-transcriptional levels. It has been suggested that selective proteolysis of SDF-1 is part of the mechanism regulating biological functions in both homeostatic and pathologic processes. The N-terminal domain of SDF-1 was shown to be efficiently processed by a number of proteases, including MMP (McQuibban et al., 2001; Zhang et al., 2003; Vergote et al., 2006) , leukocyte elastase (Valenzuela-Fernandez et al., 2002) , cathepsin G (Delgado et al., 2001) , and dipeptidyl peptidase IV (CD26) (Proost et al., 1998; Shioda et al., 1998; Sadir et al., 2004) . Structure-function analysis of SDF-1 has identified that the N-terminal region of SDF-1 (Lys 1 -Pro 2 residues) is critical for CXCR4 binding and activation (Crump et al., 1997) . Therefore, the discrete proteolysis of the SDF-1 amino terminus by these enzymes generates an inactive chemokine for CXCR4 signaling ( In this current study, we further confirmed that MMP-2 cleaved SDF-1α at Ser 4 -Leu 5 and generated a SDF-1α fragment, SDF-1(5-67) ( Figs. 1 and 2 ). SDF-1(5-67) failed to induce intracellular signaling through MAP kinase activation and cAMP accumulation (Figs. 3 and 4) in human NPCs. The failure to induce phosphorylation of ERK1/2 and Akt, which are critical for SDF-1α induced-NPC migration, resulted in failure of NPC migration induced upon SDF-1(5-67) treatment (Fig. 5) . MMP-2 efficiently converts SDF-1α from a potent chemoattractant to a molecule, SDF-1(5-67), devoid of its chemoattractant activity. These data suggest that MMP-2 may modulate the neurogenesis process through cleavage and inactivation of SDF-1. Previous studies demonstrated SDF-1(5-67) lost binding to its cognate receptor CXCR4, but induced neurotoxicity through an inducible G protein-coupled receptor CXCR3 (McQuibban et al., 2001; Vergote et al., 2006; Zhang et al., 2003) . However, human NPCs express very low level of CXCR3 as detected by real-time RT-PCR (less than 1% as compared to CXCR4 expression in NPCs and less than 11% as compared to NPC differentiated neurons, data not shown). Therefore, in our study, we did not observe a significant effect of SDF-1(5-67) on NPC viability (data not shown). This may be due to the resistance of NPCs to cell death signaling (Peng et al., 2005) and low expression of CXCR3 in human NPCs as compared to mature neurons (Vergote et al., 2006) .
During neurodegenerative disorders (for example HAD, multiple sclerosis, Parkinson's and Alzheimer's diseases), alterations in neurogenesis contribute to disease pathogenesis. Patients with HAD possess fewer adult neural progenitor cells in the dentate gyrus of the hippocampus, an important center for memory and learning, than noninfected subjects or HIV-infected patients without dementia (Krathwohl and Kaiser, 2004) . Our previous studies also demonstrated that HIV-1-infected and/or immune-activated brain macrophages affect neurogenesis through inhibition of neurogenesis and activation of gliogenesis (Peng et al., 2008) . Here we identify another important route for HIV-infected macrophages influencing neurogenesis through MMP-2 cleavage of SDF-1. Although SDF-1 has been shown to be upregulated in the brain of patients with HIV encephalitis (Langford et al., 2002; Rostasy et al., 2003) and that HIV-1 infected and activated macrophages increased expression of SDF-1 by astrocytes through IL-1β, MMP-2 is also markedly upregulated in macrophages after HIV-1 infection (Conant et al., 1999; Johnston et al., 2000) . MMP-2 efficiently converts SDF-1α to SDF-1(5-67). Removal of the four amino acids from the N-terminal of SDF-1α results in failure to induce NPC migration, which may abrogate inflammation-driven NPC migration and further repair. This observation provides evidence that HIV-1-infected and/or immune activated macrophages may affect NPC migration through post-translational regulation of SDF-1α.
MATERIALS AND METHODS
Western blot analysis of SDF-1α proteolysis
SDF-1α (1 μg) was incubated with MMP-2 (EMD Chemicals, Gibbstown, NJ) using different enzyme/substrate ratios of 1:1, 1:10 and 1:100 (w/w) and different times at 37°C in CAB (150 mmol/L NaCl, 20 mmol/L Tris, 5 mmol/L CaCl 2 , pH 7.5), as previously described (McQuibban et al., 2001) . Reaction products were electrophoresed in 15% Tris SDS-PAGE gels, transferred to an Immuno-Blot polyvinylidene fluoride (PVDF) membrane (Bio-Rad, Hercules, CA), and probed with both a polyclonal anti-SDF antibody (1:1000 dilution) to bind multiple epitopes of SDF-1α and a monoclonal anti-SDF-1 antibody (1:1000 dilution) to detect the amino-terminal part of the chemokine. Membranes were blotted with with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:10,000; Cell Signaling Technologies) and then developed using Enhanced Chemiluminescent (ECL) solution (Pierce).
RP-HPLC followed by ELISA analysis of SDF-1α proteolysis
SDF-1α (1 μg) was incubated with MMP-2 (1:10 ratio for MMP-2/SDF-1, w/w) for 4 h and the reaction products along with untreated SDF-1α were separated by RP-HPLC and collected as fractions. Different fractions were collected following HPLC and the levels of SDF-1α were determined using a monoclonal SDF-1 antibody based ELISA, as previously described (Peng et al., 2006) .
Mass spectrometry analysis of SDF-1α proteolysis
Covalent bonding of anti-SDF-1 antibody to the surface of PS10 ProteinChip ® Array (Preactivated Surface) was performed following the manufacturer's recommendations. Briefly, the chip was treated overnight with 200 ng of anti-SDF-1 polyclonal antibody (R&D Systems) per spot in a humidity box at 4°C. The spots were then blocked twice for 30 min at room temperature (RT) using fresh-made 0.5 mol/L Tris-HCl pH 8.0. Blocked spots were washed twice using 0.25% Triton X-100 in PBS. Samples were applied to each spot in a sample solution at a final concentration of 0.15% Triton X-100/PBS and incubated for 60 min at RT in a humidity box. Sample spots were washed twice with 0.25% Triton X-100 for 5 min and then briefly rinsed with HPLC grade water and allowed to dry for 5 min before application of 1 μL of 50% SPA (sinapic acid solution, 30% ACN, 15% isopropanol, 0.5% TFA) matrix to each spot. The matrix was allowed to dry and an additional 1 μL of 50% SPA was again applied to each spot and allowed to dry. Spectra were collected using PBS II ProteinChip Biosystems (Ciphergen Biosystems, city and state) mass analyzer. Analysis was performed using the Ciphergen ProteinChip ® Software.
Human neural progenitor cell culture
Human cortical NPCs were isolated from human fetal brain tissue as previously described (Peng et al., 2004) . Briefly, NPCs were cultured in substrate-free tissue culture flasks and grown as spheres in neurosphere initiation medium (NPIM), which consisted of X-Vivo 15 (BioWhittaker, Walkersville, ME) with N2 supplement (Gibco BRL, Carlsbad, CA), neural cell survival factor-1 (NSF-1, BioWhittaker), basic fibroblast growth factor (bFGF, 20 ng/mL, Sigma-Aldrich, St. Louis, MO), epidermal growth factor (EGF, 20 ng/mL, Sigma-Aldrich), leukemia inhibitory factor (LIF, 10 ng/mL, Chemicon, Temecula, CA), and 60 ng/mL N-acetylcysteine (Sigma-Aldrich). Cells were passaged at two-week intervals, as previously described (Peng et al., 2004) .
Cyclic adenosine monophosphate (cAMP) assay
The assay for cAMP accumulation was performed, as previously described, with modifications (Zheng et al., 1999; Peng et al., 2004 
Western blot for NPC signaling
NPCs were lysed with M-PER Protein Extraction Buffer (Pierce, Rockford, IL) containing 1×protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). Protein concentration was determined using the BCA Protein Assay Kit (Pierce). Proteins (10-20 μg) were separated by 10% SDS-polyacrylamide gel electrophoresis (PAGE) and then transferred to a PVDF membrane. After blocking in PBS/Tween (0.01%) with 5% nonfat milk, the membrane was incubated with primary antibodies overnight at 4°C followed by horseradish peroxidase-conjugated secondary antibodies (1:10,000; Cell Signaling Technologies) and then developed using Enhanced Chemiluminescent (ECL) solution (Pierce). For data quantification the films were scanned with a CanonScan 9950F scanner and the acquired images were then analyzed on a Macintosh computer using the public domain NIH image program (developed at the U.S. National Institutes of Health and available on the internet at http://rsb.info.nih.gov/nih-image/).
Chemotaxis assay
The in vitro migration of human NPCs in response to SDF-1α and SDF-1(5-67) was carried out using polyvinylcarbonate-free membranes with 8 µm pore size in 96-well microchemotaxis chambers (NeuroProbe, Cabin John, MD), as previously described, with modifications (Klein et al., 2001; Peng et al., 2004) . Briefly, 300 μL of Ex Vivo 15 containing 0.1% BSA with or without SDF-1α or SDF-1(5-67) was placed into the lower compartment. A 50-μL aliquot of dissociated NPC suspension (5 × 10 5 cells/mL) was added in the upper compartment of each well. For inhibition studies, cells were pretreated with 100 ng/mL of pertussis toxin (PTX) and inhibitors for 1 h. Plates were incubated at 37°C for 4 h, and migrated NPCs were counted in the lower chamber in four microscopic fields per quadruplicate well at 400X magnification. Results were expressed as mean number of cells migrating per microscopic field ± standard error of the mean (SEM).
Statistical analyses
Data were expressed as means ± SD or SEM. The data were evaluated statistically by analysis of variance (ANOVA) followed by the Tukey test for paired observations. Significance was considered to be P < 0.05. To account for any donor-specific differences, all experiments were performed with NPCs from at least three donors. All assays were performed a minimum of two times, with triplicate or quadruplicate samples in each.
